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Background: Aim of the study was to compare the short-term effects of oxygen therapy via a high-flow nasal
cannula (HFNC) on functional and subjective respiratory parameters in patients with acute hypoxic respiratory failure
in comparison to non-invasive ventilation (NIV) and standard treatment via a Venturi mask.
Methods: Fourteen patients with acute hypoxic respiratory failure were treated with HFNC (FiO2 0.6, gas flow
55 l/min), NIV (FiO2 0.6, PEEP 5 cm H2O Hg, tidal volume 6–8 ml/kg ideal body weight,) and Venturi mask (FiO2 0.6,
oxygen flow 15 l/min,) in a randomized order for 30 min each. Data collection included objective respiratory and
circulatory parameters as well as a subjective rating of dyspnea and discomfort by the patients on a 10-point scale.
In a final interview, all three methods were comparatively evaluated by each patient using a scale from 1 (=very
good) to 6 (=failed) and the patients were asked to choose one method for further treatment.
Results: PaO2 was highest under NIV (129 ± 38 mmHg) compared to HFNC (101 ± 34 mmHg, p <0.01 vs. NIV) and
VM (85 ± 21 mmHg, p <0.001 vs. NIV, p <0.01 vs. HFNC, ANOVA). All other functional parameters showed no
relevant differences. In contrast, dyspnea was significantly better using a HFNC (2.9 ± 2.1, 10-point Borg scale)
compared to NIV (5.0 ± 3.3, p <0.05), whereas dyspnea rating under HFNC and VM (3.3 ± 2.3) was not significantly
different. A similar pattern was found when patients rated their overall discomfort on the 10 point scale: HFNC
2.7 ± 1.8, VM 3.1 ± 2.8 (ns vs. HFNC), NIV 5.4 ± 3.1 (p <0.05 vs. HFNC). In the final evaluation patients gave the best
ratings to HFNC 2.3 ± 1.4, followed by VM 3.2 ± 1.7 (ns vs. HFNC) and NIV 4.5 ± 1.7 (p <0.01 vs. HFNC and p <0.05
vs. VM). For further treatment 10 patients chose HFNC, three VM and one NIV.
Conclusions: In hypoxic respiratory failure HFNC offers a good balance between oxygenation and comfort
compared to NIV and Venturi mask and seems to be well tolerated by patients.
Trial registration: German clinical trials register: DRKS00005132.
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Acute respiratory failure can be functionally classified as
hypoxic type 1 and hypercapnic type 2 respiratory failure.
Hypercapnic respiratory failure is a clear indication for
non-invasive or invasive ventilatory support, whereas the
administration of oxygen is the primary treatment in mild
and moderate hypoxic respiratory failure [1,2]. With add-
itional oxygen supply, the fraction of oxygen in inspired
air (FiO2) is raised above that of the normal atmosphere
to avoid or correct hypoxemia with subsequent tissue hyp-
oxia [3].
Oxygen applicators can be basically divided into low-
flow and high-flow devices [4]. Low-flow devices such as
nasal catheters, cannulas or simple masks deliver a limited
flow of 100% -oxygen (1 – 15 l/min maximum) which is
mixed with the total inspiratory gas flow of the patient.
The effective inspiratory oxygen concentration (EIO2) de-
pends on the respiratory flow and breathing pattern of
each individual patient and therefore is difficult to esti-
mate in advance [5].
Modern high-flow nasal cannula (HFNC) devices equip-
ped with an active humidification chamber can provide
gas flow rates up to 70 l/min, which are higher than the
patient’s respiratory flow, and therefore allow a controlled
delivery of a defined FiO2 up to 1.0, independent of the
breathing pattern of each patient [6]. HFNC might also re-
duce the work of breathing [7]. HFNC requires active
heating and humidification of the respiratory gases in
order to prevent damage of the respiratory epithelium and
reduces discomfort during therapy [8,9]. Lastly, HFNC is
increasingly used in intensive care and emergency medi-
cine [10,11].
Oxygen can also be applied via nasal, facial or full-face
masks using non-invasive ventilation (NIV). NIV has the
advantage that the use of positive end-expiratory pres-
sure (PEEP) can induce alveolar recruitment and im-
prove hypoxemia by reducing shunts. Despite these
theoretical advantages, the use of NIV in hypoxemic re-
spiratory failure is much less established than it is in hy-
percapnic respiratory failure [12-14].
In this study we compared oxygen therapy with HFNC
to NIV and Venturi mask in patients with acute hypoxicInclusion 
randomization
Baseline                  
Nasal 
prongs
Intervention Baseline      
Nasal 
prongs
15 min 15 min30 min
Figure 1 Flowchart. During the intervention patients were treated in a rand
(VM) or with none - invasive ventilation (NIV).respiratory failure. We used a short-term experimental
protocol with a focus on respiratory and circulatory pa-
rameters in combination with subjective ratings by the
patients. We specifically tried to evaluate HFNC in
terms of patient comfort and relief of dyspnea in com-
parison to established standard methods.
Methods
Patients
Patients with primary hypoxic respiratory failure (PaO2 <
55 mmHg breathing room air) of acute onset admitted to
the Medical ICU were enrolled in the present study from
March 2009 to March 2011. Patients were screened for
participation in the study during morning rounds and dur-
ing the day shift and received a standard work-up for
respiratory failure including a chest x-ray. The PaO2
of <55 mmHg breathing room air was chosen as a com-
promise between the severity of respiratory failure and
patient safety during the study protocol. Exclusion criteria
were defined as follows: clinical evidence for cardiac
pulmonary edema (history, clinical examination, chest
x-ray, echocardiography), COPD and/or ventilatory failure
(history, clinical examination, chest x-ray, PaCO2 >
50 mmHg), hemodynamic instability, contraindications to
NIV, impaired consciousness or disorientation, and inabil-
ity to give informed consent. The Ethics Committee of the
University of Tübingen approved the protocol. All sub-
jects gave informed written consent and underwent the
standard procedures of the protocol, including medical
history, review of medications, physical examination and
routine blood tests.
Study protocol
The order of the experimental protocol was randomly
assigned (Figure 1). The assignment of patients to the se-
quence in which the three oxygen applicators were applied
was randomized. Each intervention was preceded by a 15-
minute baseline period, in which oxygen was administered
via conventional nasal prongs. The gas flow was set to
achieve a peripheral oxygen saturation (SpO2) of ≥ 88%.
This gas flow was used in all subsequent baseline phases.




15 min30 min 30 min
omized order with either high-flow nasal cannula (HFNC), Venturi-mask
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turely (e.g. if they did not tolerate an oxygen applicator).
Measurements
After each baseline and intervention phase, the following
parameters were measured: arterial blood gases, heart rate,
blood pressure, respiratory rate, and peripheral oxygen sat-
uration. All data were documented in the electronic Patient
Data Management System (PDMS, CareVue®, Philips).
In addition, after each intervention patients were asked
to grade the severity of their dyspnea on a modified Borg
category ratio 10 (CR10) scale. Low numbers indicated
little dyspnea, high numbers severe dyspnea. A similar
10-point numeric rating scale (NRS) was used to grade
general discomfort related to the oxygen applicator with
low numbers indicating low discomfort. After the third
intervention, the patients were asked for a global rating
of all three applicators using a six-point rating system
(1 = very good to 6 = failed). The patients could also
choose one oxygen applicator for further treatment.
The primary endpoint was the PaO2. Secondary end-
points were respiratory rate, dyspnea (Borg-scale), dis-
comfort (10-point NRS), PaCO2, heart rate, blood
pressure, SpO2, global rating, and patient preference.
Oxygen applicators used
Standard nasal prongs (AsidBonz, Herrenberg, Germany)
with an oxygen flow of 4–12 L/min. were used for the
baseline period (Table 1). For conventional controlled oxy-
gen administration, patients received a Venturi mask
(Unomedical, Birkerød, Denmark) with an oxygen flow of
15 L/min and a FiO2 of 0.6. Both oxygen applicators were
used together with a closed sterile water system for con-
ventional bubble humidification at room temperature
(Respiflo, Covidien, Neustadt/Donau, Germany).
High - flow oxygen therapy via a HFNC (OptiFlow®,
Fisher & Paykel Healthcare Welzheim, Germany) was
administered with a FiO2 0.6 and a gas flow of 55 L/min
using an active respiratory gas humidifier (MR 850, set-
ting “invasive ventilation”, Fisher & Paykel Healthcare,
Welzheim, Germany).
For NIV, intensive care ventilators in the pressure
support mode were used according to the current
guideline for NIV in respiratory failure [14]. In all pa-
tients FiO2 was set to 0.6 and PEEP to 5 cm H2O. Five
patients were treated with a ventilator equipped specific
NIV-mode (Servo i, Maquet, Rastatt, Germany), 9 pa-
tients were treated with a ventilator without a NIV-
mode (Dräger Evita 4, Dräger, Lübeck, Germany). The
pressure support above PEEP was adjusted individually
to achieve a tidal volume of 6–8 ml/kg ideal body
weight. The interface between the patient and the venti-
lator was a commercially available mouth/nose mask
(UltraMirage NV, Resmed Martinsried, Germany). Theventilators were also equipped with an active respiratory
gas humidifier (MR 850, setting NIV, Fisher & Paykel
Healthcare Welzheim, Germany).Statistics
Data are presented as means ± standard deviations. Re-
peated measures ANOVA was used to assess the measure-
ments taken under the three different conditions (VM,
HFNC, NIV). Statistical significance was set at p < 0.05.
Post-hoc pair wise comparisons using the paired t test
were conducted only in the case of an overall significant
ANOVA result. A sample size of 14 patients had a priori
been estimated to have 80% power to detect a clinically
relevant difference of 10 mmHg in PaO2 across the 3 con-
ditions given an SD of 35 mm Hg at each level and a be-
tween level correlation of 0.80. Likewise, for both the
modified Borg CR10 dyspnea scale and the patient dis-
comfort 10-point numeric rating scale, a relevant differ-
ence of 1 scale point across the conditions given an SD of
2.5 points at each level and an between level correlation of
0.60 would be detected with 80% power, when the sample
size was 14. All analyses were performed with the JMP®
9.0 statistical software (SAS Institute, Cary, NC).Results
Fourteen patients with hypoxic type 1 respiratory failure
were enrolled in the study (Table 1). In three patients
the NIV intervention phase had to be stopped prema-
turely because the patients did not tolerate the NIV
mask. We did not observe any evidence for patient-
ventilator asynchronicity during the NIV intervention
phase. In one case, the blood gas analysis at the end of
the NIV intervention phase could not be collected in
time due to a technical problem. Measurements during
the three baseline periods did not show any significant
differences (Table 2).
PaO2 with NIV (129 ± 38 mmHg) was significantly
higher than PaO2 with HFNC (101 ± 34 mmHg, p <0.01)
(Table 2). In contrast to NIV and HFNC, PaO2 with VM
was significantly lower (85 ± 21 mmHg, P <0.001 vs.
NIV, p <0.01 vs. HFNC). The respiratory rate was
slightly, but significantly lower under NIV vs. VM (24 ±
9 vs. 28 ± 8, p < 0,01). All other cardiorespiratory and
blood gas parameters showed no relevant differences
(Table 2).
Subjective rating of dyspnea expressed on a 10-point
Borg scale was lowest under HFNC (2.9 ± 2.1), but not
significantly different to VM (3.3 ± 2.3) (Table 2). Dys-
pnea with NIV, however, was rated significantly higher
than with HFNC (5.0 ± 3.3, p <0.05). Similarily, patient
discomfort was lowest with HFNC (2.7 ± 1.8) and VM
(3.1 ± 2.8, ns vs. HFNC), and highest with NIV (5.4 ± 3.1
p <0.05 vs. HFNC).
Table 1 Patients characteristics
No Diagnosis Age BMI
[kg/m2]
SAPS II Baseline O2-flow Measurement in days
after ICU-admission




1 Idiopathic pneumonia syndrome 29 27 56 10 0 1 day, after No
2 Pneumonia (respiratory syncytial virus) 69 34 55 7 6 no Yes
3 Pneumonia (Strep. pneumoniae) 82 21 29 8 10 no Yes
4 Pneumonia 72 30 36 6 1 no Yes
5 Pneumonia (Staph. aureus) 78 30 48 12 15 no Yes
6 Pneumonia, pleural mesothelioma 71 26 54 4 1 no Yes
7 Pneumonia 76 28 55 6 0 no Yes
8 Pneumonia 50 25 45 6 1 no Yes
9 Adenocarcinoma lung 59 19 29 7 7 11 days, after No
10 Respiratory failure, myelodysplastic syndrome 68 30 43 5 6 no Yes
11 Connective tissue disease 38 29 15 8 0 no Yes
12 Pneumonia 28 29 32 5 1 no Yes
13 Pneumonia (influenza H1N1) 45 22 37 4 2 no Yes
14 Alveolar hemorrhage 18 24 43 5 4 no Yes



















Table 2 Measured variables
Bl 1 Bl 2 Bl 3 VM HFNC NIV p-value
HR [1/min] 90 ± 23 90 ± 23 89 ± 20 87 ± 21 89 ± 23 86 ± 21 ns
BPmean [mmHg] 88 ± 16 90 ± 15 86 ± 18 88 ± 13 90 ± 16 91 ± 18 ns
RR [1/min] 28 ± 9 28 ± 9 26 ± 7 28 ± 8* 26 ± 7 24 ± 9* *VM – NIV
p < 0,01
SpO2 [%] 93 ± 3 92 ± 6 93 ± 3 95 ± 4 96 ± 3 98 ± 3 ns
pH 7.47 ± 0.06 7.46 ± 0.05 7.46 ± 0.07 7.46 ± 0.06 7.46 ± 0.07 7.44 ± 0.08 ns






PaCO2 [mmHg] 36 ± 5 38 ± 5 37 ± 5 37 ± 6 37 ± 5 39 ± 7 ns
Borg scale 3.6 ± 2.5 4.3 ± 3.2 3.9 ± 2.7 3.3 ± 2.3 2.9 ± 2.1* 5.0 ± 3.3* *HFNC-NIV
p < 0,05
Patient comfort 2.5 ± 1.6 4.0 ± 1.9 4.0 ± 2.3 3.1 ± 2.8 2.7 ± 1.8* 5.4 ± 3.1* *HFNC-NIV
p < 0,05




Values are presented as means ± standard deviation, Bl baseline, VM Venturi mask, NIV Non-invasive ventilation, HFNC nasal high-flow oxygen, HR heart rate,
BPmean mean arterial blood pressure, RR respiratory rate, SpO2 peripheral oxygen saturation, PaO2 arterial pressure of oxygen, PaCO2 arterial partial pressure of
carbon dioxide.
Schwabbauer et al. BMC Anesthesiology 2014, 14:66 Page 5 of 7
http://www.biomedcentral.com/1471-2253/14/66In the final global rating, patients gave the best grades
to HFNC (2.3 ± 1.3), followed by VM (3.1 ± 1.7, ns vs.
HFNC) and NIV (4.5 ± 1.7, p <0.01 vs. HFNC and
p <0.05 vs. VM). For further treatment, 10 patients
(71%) chose HFNC (exact 95% CI: 42% to 92%), 3 chose
VM, and 1 NIV.
Discussion
In this study we investigated the effects of controlled oxy-
gen therapy with HFNC compared to Venturi mask and
NIV therapy in patients with mild to moderate acute hyp-
oxic respiratory failure. The protocol was designed to
compare the short-term effects on gas exchange and
cardio-respiratory parameters. We also conducted a sub-
jective patient evaluation of the three oxygen applications.
The PaO2 was the only gas exchange parameter that
was significantly affected by the type of oxygen applicator
despite an identical FiO2 (0.6). Not surprisingly, the high-
est PaO2 was observed under NIV, because here the PEEP
of 5 cm H20 might have led to alveolar recruitment and
reduction of intrapulmonary shunt. It has been proposed
that HFNC also can lead to some alveolar recruitment
[15]. However, in a study by Groves HFNC with a gas flow
of 60 l/min. increased airway pressures only up to 2,7 cmH2O while breathing with an open mouth, and 7.4 cm
H2O with the mouth closed. This increase in airway pres-
sure was considered negligible [16]. Nevertheless, a recent
study of Riera and coworkers [17] shows an increase in
end-exspiratory lung volume, messured by electrical im-
pedance tomography (EIT), presumably due to the higher
airway pressure levels.
The higher PaO2 observed under HFNC, compared to a
Venturi mask, can be explained by the higher adminis-
tered gas flows (up to 55 l/min). With a Venturi mask and
an oxygen flow of 15 l/min the targeted FiO2 of 0.6 can
only be achieved when the total gas flow is not higher
than 30 L/min. In acute hypoxic respiratory failure often
much higher inspiratory gas flows are generated. Espe-
cially in Venturi systems and other masks that are not
tight fitting, this leads to an additional room-air admixture
during inspiration resulting in a reduction of FiO2 [6].
In our patients with mild to moderate acute hypoxic re-
spiratory failure, all oxygen application systems were able
to increase the mean PaO2 into the horizontal upper part
of the oxygen binding curve, so that a normal mean arter-
ial oxygen saturation (SaO2) of ≥ 95% could be achieved
with all oxygen applicators. This might explain why we
did not observe any relevant differences regarding the
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rate, PaCO2) during the short observation period of just
30 minutes. A notable effect on these parameters was
found in other studies [11,18-21] of more severe forms of
hypoxic respiratory failure. In these studies, differences in
the PaO2 attributable to the type of oxygen applicator
affect the SaO2 in the steep part of the oxygen binding
curve. In such patients, a higher SaO2 might reduce hyp-
oxic respiratory drive. However, patients with these more
severe forms of hypoxic respiratory failure were excluded
from our study, because they are usually under severe dis-
tress and not able to comply with the experimental
protocol.
With respect to patient comfort and satisfaction, in our
study HFNC received the best subjective ratings regarding
dyspnea, discomfort and general evaluation and was pre-
ferred by a large majority of the patients for further oxygen
supplementation. Compared to Venturi mask, however, the
differences were not statistically significant. We hypothesize
that improved humidification of the respiratory gas using
HFNC might have a minor positive effect on patient com-
fort. Chanques et al. investigated the effect of an active hu-
midification system compared to a conventional bubble
humidifier during oxygen therapy via a face mask using a
gas flow of 5–11 l/min. Active humidification resulted in
less symptoms of dehydration of the upper respiratory tract
and significantly increased comfort for the patients [22].
Cuquemelle et al. similarily showed increased patient com-
fort when standard oxygen therapy via the nasal airways
with no humidification was compared with HFNC with
heated and humidified oxygen [8]. The positive effect of
HFNC on respiratory gas humidification, however, might
be offset by other factors affecting patient comfort such as
an increased noise level which often is a problem at least
with older HFNC systems. Other studies, however, also
have shown that HFNC is well tolerated and effective in re-
lieving dyspnea when compared to oxygen therapy via
standard face masks [11,20]. In the study by Lenglet et al.
patients with acute hypoxic respiratory failure were treated
in the emergency department first with a non-rebreathing
mask and were then switched to HFNC. HFNC was pre-
ferred by 76% of the healthcare givers.
Our study so far is the first study to compare HFNC
with NIV in the setting of acute hypoxic respiratory fail-
ure, NIV received the worst subjective ratings in all
categories although it led to the best improvement in
oxygenation. Three patients terminated the NIV phase
of the study early due to intolerance of the application.
It should be noted that the adaptation phase to the NIV
mask in our protocol was very short. So, it is possible
that an individual optimization of the NIV parameters
and a longer adaptation phase might have resulted in
improved patient tolerance and comfort. However, pa-
tients with hypoxic respiratory failure often requireprolonged periods of respiratory support, which many pa-
tients do not tolerate on NIV. In clinical practice we often
use a combination of NIV and HFNC in patients with mod-
erate to severe hypoxic respiratory failure in whom we are
trying to avoid intubation (e.g. immunocompromised pa-
tients) [23,24]. A beneficial effect of NIV on dyspnea has
also been shown in end-of-life patients with solid tumors,
however, it was not compared to HFNC in this study set-
ting [25]. Intermittent phases with HFNC helped to prevent
skin damage, allow the patients to cough, eat, and commu-
nicate, and thus might increase patient compliance.
Our study was designed as a short term experimental
study and therefore has several limitations. The dur-
ation of the interventions was with 30 minutes very
short. Longer durations, however, would have made
direct comparisons of the measurements more difficult.
In addition, for patients in acute respiratory distress it
was problematic to comply with a longer experimental
protocol. Our study did not address questions regarding
the correct indication for HFNC and its long-term ef-
fects. Several recent studies have demonstrated that
HFNC can be applied safely in many patients with acute
hypoxic respiratory failure including influenza H1N1
pneumonia [20,21]. Patients with severe respiratory fail-
ure, however, may still require mechanical ventilation. A
recent experimental study showed that in mild lung
injury spontaneous breathing improved lung recruit-
ment. In severe lung injury, however, accelerated
spontaneous ventilation induced more lung injury than
lung-protective mechanical ventilation including muscle
paralysis. High tidal volumes under spontaneous venti-
lation led to high transpulmonary pressures with signifi-
cant stress and strain on the injured lung. The lack of a
PEEP also promoted atelectasis and cyclic alveolar col-
lapse. Finally, application of a high FiO2 up to 1.0, which
is possible with HFNC, might further accelerate lung in-
jury [26].Conclusion
HFNC is a well tolerated and an effective device for oxy-
gen therapy in mild to moderate hypoxic respiratory fail-
ure and bridges the gap between conventional oxygen
applicators, NIV, and invasive mechanical ventilation. The
indications and contraindications for HFNC have to be
further clarified in additional clinical outcome studies.Abbreviations
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RR: Respiratory rate; SpO2: Peripheral oxygen saturation; PaO2: Arterial partial
pressure of oxygen; PaCO2: Arterial partial pressure of carbon dioxide.
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